CN111653360A - Intervention system based on brain health risk assessment - Google Patents
Intervention system based on brain health risk assessment Download PDFInfo
- Publication number
- CN111653360A CN111653360A CN202010457655.7A CN202010457655A CN111653360A CN 111653360 A CN111653360 A CN 111653360A CN 202010457655 A CN202010457655 A CN 202010457655A CN 111653360 A CN111653360 A CN 111653360A
- Authority
- CN
- China
- Prior art keywords
- brain health
- risk
- intervention
- brain
- health
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036995 brain health Effects 0.000 title claims abstract description 255
- 238000012502 risk assessment Methods 0.000 title claims abstract description 40
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 50
- 238000001514 detection method Methods 0.000 claims abstract description 40
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 32
- 101150037123 APOE gene Proteins 0.000 claims abstract description 24
- 238000011156 evaluation Methods 0.000 claims abstract description 11
- 235000015097 nutrients Nutrition 0.000 claims description 29
- 239000002131 composite material Substances 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 239000006041 probiotic Substances 0.000 claims description 10
- 235000018291 probiotics Nutrition 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 108010024636 Glutathione Proteins 0.000 claims description 7
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 235000006694 eating habits Nutrition 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 102200017290 rs429358 Human genes 0.000 claims description 5
- 102200017284 rs7412 Human genes 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 235000021323 fish oil Nutrition 0.000 claims description 4
- 230000000529 probiotic effect Effects 0.000 claims description 4
- 108700028369 Alleles Proteins 0.000 claims description 2
- 238000012552 review Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 2
- 230000036541 health Effects 0.000 description 11
- 102100029470 Apolipoprotein E Human genes 0.000 description 6
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 208000027061 mild cognitive impairment Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 101710095339 Apolipoprotein E Proteins 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/60—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
Landscapes
- Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Primary Health Care (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses an intervention system based on brain health risk assessment, which comprises: the brain health exogenous risk assessment module is used for reading a brain health scientific questionnaire of a detected person, calculating a brain health risk score corresponding to the brain health scientific questionnaire according to a brain health risk judgment standard, and obtaining a brain health exogenous risk grade according to the brain health risk score; the brain health endogenous risk assessment module is used for carrying out gene detection on the APOE gene highly associated with the brain health and obtaining the brain health endogenous risk level according to the gene detection result; the brain health comprehensive risk evaluation module is used for obtaining a brain health comprehensive risk grade according to the brain health exogenous risk grade and the brain health endogenous risk grade; and the brain health intervention scheme output module is used for outputting a brain health intervention scheme according to the brain health comprehensive risk level. The method can more accurately evaluate the brain health risk level of the examinee and effectively prevent the occurrence of Alzheimer's disease.
Description
Technical Field
The invention belongs to the technical field of computer medical service, and particularly relates to an intervention system based on brain health risk assessment.
Background
At present, accurate health management of brain health from the perspective of genomics mainly focuses on revealing the action mechanism of genetic factors in disease occurrence and development, accurately predicts the risk of disease occurrence from the perspective of disease occurrence genetics by detecting highly-associated genetic loci with disease occurrence and development, and provides health management suggestions in the aspects of diet, life style, physical examination and the like by taking gene detection results as guidance, so that chronic diseases are delayed or not generated, and the fatality disability rate of diseases is reduced.
According to the statistics of the international alzheimer's disease association, 5000 more than ten thousand alzheimer's disease patients exist internationally, and the increase to 1.4 hundred million is expected in 2050. By 2019, more than 1000 million alzheimer patients are expected to be the countries with the largest number of patients in China, and in 2050, 2800 million patients are expected to be in China, while the conservation of the mild cognitive impairment population between the normal aging and the alzheimer disease is expected to reach 1.78 hundred million (the incidence of Chinese population is about 12.7%, and the mild cognitive impairment is recorded in the early recognition and intervention). At present, Alzheimer's disease cannot be cured radically, so that the early discovery and early prevention are the key points. Early detection of alzheimer's disease is not very difficult under current medical conditions. In addition to routine examination, in clinical work, genetic testing is performed on the middle-aged and old people with mild cognitive impairment, apolipoprotein E (Apolipoprotein E, APOE for short) is a Very important polymorphic protein in body species, is a single-chain polypeptide glycoprotein containing 299 amino acids, is mainly present in Very Low Density Lipoprotein (VLDL), Chylomicron (CM for short) and High Density Lipoprotein (HDL for short), is involved in the conversion and metabolism of Lipoprotein, plays an important role in regulating lipid metabolism, and is also closely related to the occurrence of Alzheimer's disease. The APOE gene transports cholesterol to the body where it is needed, just like a transport stream. The APOE mutation can not normally complete the transportation task, and excessive cholesterol is accumulated in blood, and the blood flow obstruction can cause diseases such as coronary heart disease, cerebral infarction, Alzheimer disease, hyperlipidemia, etc. As can be seen, the APOE gene is a high-association risk gene of the Alzheimer disease, and has higher accuracy in predicting the late onset of the Alzheimer disease. APOE genes can be divided into three genotypes: the APOE2 type, the APOE3 type and the APOE4 type are discovered in genomics research, the APOE4 genotype can obviously increase the occurrence of delayed Alzheimer's disease, the APOE2 genotype can effectively prevent the occurrence of delayed Alzheimer's disease, the APOE 3552 genotype is a protective factor of the Alzheimer's disease, the APOE3 genotype is not easy to cause the occurrence of the Alzheimer's disease and is a normal factor of the body, wherein the lifetime risk of the Alzheimer's disease of a carrier of the APOE4 genotype is increased to 30%, and the lifetime risk of the Alzheimer's disease is increased to more than 50% if the carrier is homozygous with APOE4, so that the APOE2 type, the APOE3 type and the APOE4 type are greatly earlier than common people in onset time. China is expected to carry a high risk population of APOE4 type with cognitive decline up to 2.35 hundred million risks. The us FDA was approved in 2017 for APOE gene testing as a consumer-oriented gene test.
However, since the gene chip detection technology adopted by 23 andsme company, which was first approved by FDA, sites related to APOE gene are located in a region with high GC content, and the ratio of Guanine (G) to Cytosine (C) is referred to as GC content, which affects the interpretation of the genotype of the sites in the chip. China has a plurality of gene detection products for consumers, and most of the products adopt the same gene chip technical means as those of the United states at present, so that the APOE genotyping result of part of users is lost. More importantly, most of the gene detection products and services oriented to consumers in the market are entertainment-oriented or only provide susceptible gene risk assessment results, and the discordant health management means are common-sense health education, lack of deep health management scientific research and cannot play a role in effective personalized prevention and intervention, so that the consumers have doubts about health management values.
Disclosure of Invention
In order to solve the above problems in the prior art, the present invention provides an intervention system based on brain health risk assessment.
One embodiment of the present invention provides an intervention system based on brain health risk assessment, the system comprising:
the brain health exogenous risk assessment module is used for reading a brain health scientific questionnaire of a detected person, calculating a brain health risk score corresponding to the brain health scientific questionnaire according to a brain health risk judgment standard, and obtaining a brain health exogenous risk grade according to the brain health risk score;
the brain health endogenous risk assessment module is used for carrying out gene detection on the APOE gene highly associated with the brain health and obtaining the brain health endogenous risk level according to the gene detection result;
the brain health comprehensive risk evaluation module is used for obtaining a brain health comprehensive risk grade according to the brain health exogenous risk grade and the brain health endogenous risk grade;
and the brain health intervention scheme output module is used for outputting a brain health intervention scheme according to the brain health comprehensive risk level.
In one embodiment, the system further comprises:
and the storage module is used for storing the brain health intervention scheme and forming a brain health intervention archive library so as to provide tracking management service for the examinee.
In one embodiment, the system further comprises a brain health management module for implementing online management of the output brain health intervention program for online viewing by the subject.
In one embodiment, the brain health management module is further configured to update the brain health intervention archive in the storage module.
In a specific embodiment, the brain health science questionnaire comprises lifestyle, diseases that cause high incidence of alzheimer's disease, family history of alzheimer's disease, physical examination indices and personal factors.
In a specific embodiment, the brain health extrinsic risk level includes extrinsic high risk, extrinsic medium risk, and extrinsic low risk, wherein the brain health extrinsic risk level is determined from the brain health risk score.
In one embodiment, the brain health intrinsic risk assessment module is specifically configured to:
detecting the genotypes of an rs429358 locus and an rs7412 locus of an APOE gene, namely an APOE2 type, an APOE3 type and an APOE4 type, wherein the detection loci comprise homozygous phenotypes or heterozygous phenotypes obtained by isomerizing alleles 2, 3and 4, wherein the homozygous phenotypes comprise 2/2, 3/3 and 4/4, and the heterozygous phenotypes comprise 2/3, 2/4 and 3/4;
when the gene detection result is 4/4, determining the internal cause risk grade of the brain health as the internal cause high risk; when the gene detection result is 2/4 and 3/4, determining the internal cause risk grade of the brain health as the internal cause risk; when the gene detection result is 2/2, 2/3 and 3/3, the internal cause risk grade of the brain health is determined as the internal cause low risk.
In a specific embodiment, the brain health composite risk level comprises composite high risk, composite medium risk, composite low risk;
the brain health intervention program comprises: lifestyle intervention, dietary habit intervention, physical examination content intervention, and,
when the brain health comprehensive risk level is comprehensive high risk, the brain health intervention scheme further comprises first nutrient intervention, wherein the first nutrient intervention comprises a norhomocysteine compound preparation, probiotics and a compound antioxidant preparation;
when the brain health comprehensive risk level is the comprehensive risk, the brain health intervention scheme further comprises second nutrient intervention, wherein the second nutrient intervention comprises a norhomocysteine complex preparation, probiotics and reduced glutathione;
when the brain health composite risk level is at risk in the composite and has diabetes, the brain health intervention scheme further comprises a third nutrient intervention, wherein the third nutrient intervention comprises a homocysteine-lowering composite preparation, a probiotic and a blood sugar control composite preparation;
when the brain health composite risk level is a composite low risk, the brain health intervention program further comprises a fourth nutrient intervention, wherein the fourth nutrient intervention comprises reduced glutathione, fish oil.
Compared with the prior art, the invention has the beneficial effects that:
the intervention system based on brain health risk assessment combines the brain health scientific questionnaire with the APOE gene detection to comprehensively assess the brain health risk level of the examinee, and realizes intelligent brain health risk assessment and intervention based on the brain health intervention scheme library, and the output brain health intervention scheme is more suitable for the examinee, thereby more effectively preventing the Alzheimer's disease.
The present invention will be described in further detail with reference to the accompanying drawings and examples.
Drawings
Fig. 1 is a schematic structural diagram of an intervention system based on brain health risk assessment according to an embodiment of the present invention;
fig. 2 is a schematic structural diagram of another intervention system based on brain health risk assessment according to an embodiment of the present invention.
Detailed Description
The present invention will be described in further detail with reference to specific examples, but the embodiments of the present invention are not limited thereto.
Example one
In order to better prevent alzheimer's disease and reduce morbidity, there is a need for a product that can cover brain health management and perform targeted personalized health management on alzheimer's disease population in terms of high-precision health management. Referring to fig. 1, fig. 1 is a schematic structural diagram of an intervention system based on brain health risk assessment according to an embodiment of the present invention, which provides an intervention system based on brain health risk assessment according to the embodiment of the present invention, the intervention system based on brain health risk assessment includes a brain health exogenous risk assessment module, a brain health endogenous risk assessment module, a brain health comprehensive risk assessment module, and a brain health intervention plan output module, wherein,
the brain health exogenous risk assessment module is used for reading a brain health scientific questionnaire of a detected person, calculating a brain health risk score corresponding to the brain health scientific questionnaire according to a brain health risk judgment standard, and obtaining a brain health exogenous risk grade according to the brain health risk score.
Specifically, the examinee in this embodiment may input basic information, which may include, for example, form filling date, name, sex, age, height (cm) and weight (kg), in a system providing an interactive function such as a web page or an APP client, and fill in a brain health science questionnaire at the client, it should be noted that the name of the brain health science questionnaire defined in this embodiment is only one code expression, and may be a questionnaire with other names, as long as the questionnaire content in this embodiment is included.
For the reading of the questionnaire data, since the format of the questionnaire data of the embodiment is fixed, the corresponding area or the corresponding field can be read by the preset reading rule to obtain the content of the questionnaire survey.
The brain health science questionnaire is an questionnaire about risk factors of alzheimer's disease, and specifically the brain health science questionnaire includes lifestyle, diseases causing high-grade alzheimer's disease, alzheimer's disease family history, physical examination index and personal factors, wherein the lifestyle may include drinking, smoking, exercise condition, social condition, etc., the diseases causing high-grade alzheimer's disease may include brain trauma (severe/general), cerebral apoplexy/hypertension/diabetes, herpes virus infection, etc., the alzheimer's disease family history may include 1 person in the immediate family suffering from alzheimer's disease, 2 or more persons in the immediate family suffering from alzheimer's disease, etc., and the physical examination index may include homocysteine value (less than 6 μmol/L/6-15 μmol/L/more than 15 μmol/L within 3 months), The electroencephalogram shows diffuse slow waves, and personal factors include sex (female), age (more than 50-65/65-80/80), and the like.
Of course, the above is merely illustrative, and in specific implementations, the questionnaire content can be adjusted according to actual situations, for example, part of options can be added or deleted, so as to provide more targeted surveys and improve the reliability of questionnaires.
In this embodiment, after the client fills in the brain health science questionnaire, the brain health science questionnaire input by the subject at the client is read on the server, and on the server, the brain health risk determination criteria respectively correspond to the lifestyle in the brain health science questionnaire, the disease causing the high incidence of alzheimer's disease, the family history of alzheimer's disease, the physical examination index, and the personal factor, and are provided with reference risk values.
The reference risk value is reflected in the form of an integral in the present embodiment, and the setting of the integral may also be determined according to specific situations, for example, an option with a heavier weight value, a larger integral value may be set, an option with a lighter weight value, and a smaller integral value may be set, which is described below by taking an integral manner as an example.
For example, the reference risk values specifically set for the brain health risk assessment criteria, such as drinking, smoking, exercise, and social situations in lifestyle, are all set to 1 point, the reference risk values for traumatic brain injury (severe/general), anemia/stroke/hypertension/diabetes, and herpes virus infection, which are the most common diseases of alzheimer's disease, are set to 3/1, 1/1//1, and 1 point, respectively, the reference risk values for alzheimer's disease in 1 person of the immediate family history and 2 or more persons of the immediate family history are set to 3and 5 points, and the reference risk values for homocysteine values in physical examination indices (less than 6 μmol/L/6 to 15 μmol/L/greater than 15 μmol/L within 3 months) are set to 3and 5 points, respectively, Reference risk values corresponding to diffuse slow waves appearing in the electroencephalogram are set to be 0/1/3 and 3 points respectively, and reference risk values corresponding to gender (women) and age (more than 50-65/65-80/80) in personal factors are set to be 1 and 1/2/3 points respectively.
For example, a 55 year old female subject, the information fed back by the brain health science questionnaire includes: in the diseases of anemia and hypertension in which the Alzheimer disease is caused by improper diet and lack of exercise in the lifestyle, the family does not have the information of the immediate relatives suffering from the Alzheimer disease, and the blood homocysteine value in the physical examination index is 16 mu mol/L, so that the brain health risk integral corresponding to the brain health scientific questionnaire is calculated to be 1+1+1+1+1+ 3-9 according to the reference risk value.
Further, in this embodiment, the preset brain health questionnaire determination standard is adopted to determine the brain health risk score to obtain the brain health exogenous risk level, and specifically, the preset brain health questionnaire determination standard is as follows:
when the brain health risk score is greater than or equal to a first threshold, the brain health exogenous risk level is an exogenous high risk; when the brain health risk score is less than or equal to a second threshold, the brain health exogenous risk level is exogenous low risk; and when the brain health risk score is less than the first threshold and greater than the second threshold, the brain health exogenous risk level is an exogenous risk. For example, the first threshold setting value is 15 minutes, the second threshold setting value is 9 minutes, if the score of the brain health questionnaire is 9 minutes, the external cause risk level of the brain health of the subject is the external cause low risk, if the score of the brain health questionnaire is 14 minutes, the external cause risk level of the brain health of the subject is the external cause medium risk, and so on, the external cause risk level of the brain health of each subject is obtained.
In the embodiment, the brain health scientific questionnaire is carried out on a group of examinees, so that the influence of the examinees on the exogenous factors is paid attention to in real time, the risk level of the Alzheimer's disease influenced by the exogenous factors is clarified, and the occurrence of the Alzheimer's disease is judged according to the risk level of the exogenous factors, thereby effectively preventing the occurrence of the Alzheimer's disease.
And the brain health endogenous risk assessment module is used for carrying out gene detection on the APOE gene highly associated with the brain health and obtaining a brain health endogenous risk grade according to a gene detection result.
Specific evaluation principles and evaluation procedures are exemplified as follows:
genetically, the occurrence of alzheimer's disease is highly related to APOE gene located on chromosome 19, and polymorphism of APOE gene is determined by rs429358 site and rs7412 site, and international universal typing rules are: the combination is 2/2 type when the detection result of the rs429358 site and the rs7412 site is TT and TT; the TT and TC are combined into 2/3 type; the combination of TT and CC is 3/3 type; the TC and the TC are combined into 2/4 type; the TC and the CC are combined into 3/4 type; CC. The CC combination is 4/4 type. A total of six different genotypes were generated, also corresponding to different risk classes.
Therefore, in the gene detection of this embodiment, six gene detection results of 2/2, 2/3, 2/4, 3/3, 3/4 and 4/4 are obtained after the gene detection of the rs429358 site and the rs7412 site of the APOE gene is performed by using the qPCR gene detection technology.
When the gene detection result is 4/4, determining the internal cause risk grade of the brain health as the internal cause high risk; when the gene detection result is 2/4 and 3/4, determining the internal cause risk grade of the brain health as the internal cause risk; when the gene detection result is 2/2, 2/3 and 3/3, the internal cause risk grade of the brain health is determined as the internal cause low risk.
And the brain health comprehensive risk evaluation module is used for obtaining a brain health comprehensive risk grade according to the brain health exogenous risk grade and the brain health endogenous risk grade.
Because the alzheimer disease belongs to a complex disease, the occurrence and development of the alzheimer disease are the result of combined action of internal factors and external factors, the internal factors are mainly determined by inheritance and variation of genes, and the external factors are mainly influenced by environmental risk factors, bad life style and the like, the internal factors and the external factors are comprehensively considered, so that the occurrence of the alzheimer disease is effectively prevented, wherein the brain health external factor risk grade is obtained through the brain health external factor risk evaluation module, the brain health internal factor risk grade is obtained through the brain health internal factor risk evaluation module, then the brain health external factor risk grade and the brain health internal factor risk grade are comprehensively considered to obtain the brain health comprehensive risk grade, and the occurrence condition of the alzheimer disease can be more accurately determined through the brain health comprehensive risk grade. Specifically, a preset brain health comprehensive risk judgment standard is adopted to judge the brain health exogenous risk level and the brain health endogenous risk level to obtain a brain health comprehensive risk level, the brain health comprehensive risk level comprises a comprehensive high risk, a comprehensive medium risk and a comprehensive low risk, and the preset brain health comprehensive risk judgment standard is as follows:
when the external cause risk grade of the brain health is external cause low risk and the internal cause risk grade of the brain health is internal cause low risk, the comprehensive risk grade of the brain health is comprehensive low risk; when the external cause risk grade of the brain health is the external cause intermediate risk or the high risk, the internal cause risk grade of the brain health is the internal cause low risk, the external cause risk grade of the brain health is the external cause low risk and the internal cause risk grade of the brain health is the internal cause intermediate risk, the comprehensive risk grade of the brain health is the comprehensive intermediate risk; when the external cause risk grade of the brain health is external cause low risk, the internal cause risk grade of the brain health is internal cause high risk, the external cause risk grade of the brain health is external cause middle risk, the internal cause risk grade of the brain health is internal cause middle risk or internal cause high risk, the external cause risk grade of the brain health is external cause high risk, the internal cause risk grade of the brain health is internal cause middle risk or internal cause high risk, and the comprehensive risk grade of the brain health is comprehensive high risk.
According to the embodiment, the comprehensive consideration of the brain health science questionnaire survey and the APOE gene detection is carried out on the population of the examinees, the content of the evaluation of the illness risk level of the examinees is enriched through the comprehensive consideration of the external factors and the internal factors, the evaluation result is more accurate than that of the evaluation carried out by the external factors or the internal factors alone, and the occurrence of the Alzheimer disease is more effectively prevented.
Specifically, there are great differences in brain health intervention schemes for different subjects, and therefore, the present embodiment provides a comprehensive brain health intervention scheme library that can be oriented to any group of people, where the database includes lifestyle intervention, dietary habit intervention, physical examination content intervention, such as prompting less smoking, less drinking, strengthening exercise, etc., the dietary habit intervention, such as prompting less oil, less salt, less sugar, multiple proteins, etc., the physical examination content intervention, such as prompting blood homocysteine level detection, blood glucose detection, craniocerebral CT or nuclear magnetic resonance, etc., and for different subjects, the corresponding lifestyle intervention, dietary habit intervention, physical examination content intervention schemes may be the same or different, and are specifically determined by brain health scientific questionnaire and APOE gene detection results of the subject.
Meanwhile, a dietary nutrition intervention scheme is also provided in the brain health intervention scheme library, and a personalized dietary nutrition intervention scheme is provided according to different requirements of the examinee, so that the examinee can be better helped to prevent the Alzheimer disease.
And the brain health intervention scheme output module is used for outputting the customized brain health intervention scheme according to the brain health comprehensive risk level and the brain health intervention scheme library.
Specifically, at present, an individualized accurate brain health intervention scheme is not available for alzheimer disease, and most of the cases stagnate that after alzheimer disease is detected, a detection result is provided by a subject to perform detection result analysis by a professional doctor. In this embodiment, the brain health intervention plan is output from the brain health intervention plan library by judging the brain health comprehensive risk level, specifically:
the brain health comprehensive risk level comprises comprehensive high risk, comprehensive medium risk and comprehensive low risk;
the brain health intervention program comprises: lifestyle intervention, dietary habit intervention, physical examination content intervention, and,
when the brain health comprehensive risk level is comprehensive high risk, the brain health intervention scheme further comprises first nutrient intervention, wherein the first nutrient intervention comprises a norhomocysteine compound preparation, probiotics and a compound antioxidant preparation;
when the brain health comprehensive risk level is the comprehensive risk, the brain health intervention scheme further comprises second nutrient intervention, wherein the second nutrient intervention comprises a norhomocysteine complex preparation, probiotics and reduced glutathione;
when the brain health composite risk level is at risk in the composite and has diabetes, the brain health intervention scheme further comprises a third nutrient intervention, wherein the third nutrient intervention comprises a homocysteine-lowering composite preparation, a probiotic and a blood sugar control composite preparation;
when the brain health composite risk level is a composite low risk, the brain health intervention program further comprises a fourth nutrient intervention, wherein the fourth nutrient intervention comprises reduced glutathione, fish oil.
It should be noted that, in the present embodiment, the homocysteine-lowering complex formulation, the probiotic, the complex antioxidant formulation, the reduced glutathione, the fish oil, the blood sugar control complex formulation, and the like mentioned in the first nutrient intervention, the second nutrient intervention, the third nutrient intervention, and the fourth nutrient intervention are not limited to the names of the types thereof, as long as the functions are realized, that is, the nutrients provided above are not limited.
In summary, the intervention system based on brain health risk assessment provided by this embodiment combines the brain health science questionnaire with APOE gene detection, and specifically, when performing brain health risk assessment, obtains an exogenous assessment risk level through the brain health science questionnaire, obtains an endogenous assessment risk level through APOE gene detection, comprehensively assesses the brain health risk level of the subject through the exogenous assessment risk level and the endogenous assessment risk level, and provides a high-precision brain health intervention scheme suitable for the subject based on the brain health intervention scheme library, thereby effectively preventing the occurrence of alzheimer disease.
Further, referring to fig. 2, fig. 2 is a schematic structural diagram of another intervention system based on brain health risk assessment according to an embodiment of the present invention, where the intervention system based on brain health risk assessment according to the embodiment further includes: and the storage module is used for storing the brain health intervention scheme and forming a brain health intervention archive library so as to provide tracking management service for the examinee.
And the health management module is used for realizing online management on the output brain health intervention scheme so as to enable the examinee to check the brain health intervention scheme online.
At present, brain health management products related to chronic diseases still stay at the level of issuing electronic PDF reports and offline paper reports, and the issuing form of the reports is more prone to online reports which are suitable for being checked by mobile phones at any time on APP. The brain health management module can provide an online report for the examinee, establish a brain health electronic file for the examinee, provide services such as regular health consultation and the like, and the examinee can check the health management report on the mobile phone APP at any time.
Meanwhile, after intervention for a certain time (for example, half a year), the subject can check the intervention effect through a brain health intervention scheme given half a year ago through detection modes such as physical examination and the like, and feeds back the latest brain health science questionnaire through the client again, and then combines APOE gene detection, so that the more accurate brain health intervention scheme required at present is optimized and output.
The brain health management module of the embodiment is further configured to update the brain health intervention plan library in the brain health intervention plan storage module. The brain health management module can monitor the brain health research result at the global frontier in real time, and update the monitored intervention scheme more favorable for the examinee into the brain health intervention scheme library, and the brain health intervention scheme library can output a more accurate and personalized brain health intervention scheme for the examinee, so that the occurrence of Alzheimer's disease is effectively prevented.
It should be noted that in the description of the present specification, reference to the description of the term "one embodiment", "some embodiments", "example", "specific example", or "some examples", etc., means that a particular feature or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present application. In this specification, the schematic representations of the terms used above are not necessarily intended to refer to the same embodiment or example. Furthermore, the particular features or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, various embodiments or examples described in this specification can be combined and combined by those skilled in the art.
While the present application has been described in connection with various embodiments, other variations to the disclosed embodiments can be understood and effected by those skilled in the art in practicing the claimed application, from a review of the drawings, the disclosure, and the appended claims. In the claims, the word "comprising" does not exclude other elements or steps, and the word "a" or "an" does not exclude a plurality. A single processor or other unit may fulfill the functions of several items recited in the claims. The mere fact that certain measures are recited in mutually different dependent claims does not indicate that a combination of these measures cannot be used to advantage.
The foregoing is a more detailed description of the present application in connection with specific preferred embodiments and it is not intended that the present application be limited to these specific details. For those skilled in the art to which the present application pertains, several simple deductions or substitutions may be made without departing from the concept of the present application, and all should be considered as belonging to the protection scope of the present application.
Claims (8)
1. An intervention system based on brain health risk assessment, comprising:
the brain health exogenous risk assessment module is used for reading a brain health scientific questionnaire of a detected person, calculating a brain health risk score corresponding to the brain health scientific questionnaire according to a brain health risk judgment standard, and obtaining a brain health exogenous risk grade according to the brain health risk score;
the brain health endogenous risk assessment module is used for carrying out gene detection on the APOE gene highly associated with the brain health and obtaining the brain health endogenous risk level according to the gene detection result;
the brain health comprehensive risk evaluation module is used for obtaining a brain health comprehensive risk grade according to the brain health exogenous risk grade and the brain health endogenous risk grade;
and the brain health intervention scheme output module is used for outputting a brain health intervention scheme according to the brain health comprehensive risk level.
2. The brain health risk assessment based intervention system of claim 1, further comprising:
and the storage module is used for storing the brain health intervention scheme and forming a brain health intervention archive library so as to provide tracking management service for the examinee.
3. The intervention system based on brain health risk assessment according to claim 2, further comprising a brain health management module for enabling online management of the outputted brain health intervention program for online review by a subject.
4. The brain health risk assessment based intervention system of claim 3, wherein the brain health management module is further configured to update the repository of brain health intervention archives in the storage module.
5. The intervention system based on brain health risk assessment according to claim 1, wherein the brain health science questionnaire comprises lifestyle, diseases causing high incidence of alzheimer's disease, family history of alzheimer's disease, physical examination indices and personal factors.
6. The intervention system based on brain health risk assessment according to claim 1, wherein the brain health extrinsic risk levels comprise extrinsic high risk, extrinsic medium risk, extrinsic low risk, wherein the brain health extrinsic risk levels are determined from the brain health risk score.
7. The brain health risk assessment based intervention system of claim 1, wherein the brain health endogenous risk assessment module is specifically configured to:
detecting the genotypes of an rs429358 locus and an rs7412 locus of an APOE gene, namely an APOE2 type, an APOE3 type and an APOE4 type, wherein the detection loci comprise homozygous phenotypes or heterozygous phenotypes obtained by isomerizing alleles 2, 3and 4, wherein the homozygous phenotypes comprise 2/2, 3/3 and 4/4, and the heterozygous phenotypes comprise 2/3, 2/4 and 3/4;
when the gene detection result is 4/4, determining the internal cause risk grade of the brain health as the internal cause high risk; when the gene detection result is 2/4 and 3/4, determining the internal cause risk grade of the brain health as the internal cause risk; when the gene detection result is 2/2, 2/3 and 3/3, the internal cause risk grade of the brain health is determined as the internal cause low risk.
8. The intervention system based on brain health risk assessment according to claim 1, wherein the brain health composite risk level comprises composite high risk, composite medium risk, composite low risk;
the brain health intervention program comprises: lifestyle intervention, dietary habit intervention, physical examination content intervention, and,
when the brain health comprehensive risk level is comprehensive high risk, the brain health intervention scheme further comprises first nutrient intervention, wherein the first nutrient intervention comprises a norhomocysteine compound preparation, probiotics and a compound antioxidant preparation;
when the brain health comprehensive risk level is the comprehensive risk, the brain health intervention scheme further comprises second nutrient intervention, wherein the second nutrient intervention comprises a norhomocysteine complex preparation, probiotics and reduced glutathione;
when the brain health composite risk level is at risk in the composite and has diabetes, the brain health intervention scheme further comprises a third nutrient intervention, wherein the third nutrient intervention comprises a homocysteine-lowering composite preparation, a probiotic and a blood sugar control composite preparation;
when the brain health composite risk level is a composite low risk, the brain health intervention program further comprises a fourth nutrient intervention, wherein the fourth nutrient intervention comprises reduced glutathione, fish oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010457655.7A CN111653360A (en) | 2020-05-26 | 2020-05-26 | Intervention system based on brain health risk assessment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010457655.7A CN111653360A (en) | 2020-05-26 | 2020-05-26 | Intervention system based on brain health risk assessment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111653360A true CN111653360A (en) | 2020-09-11 |
Family
ID=72350880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010457655.7A Pending CN111653360A (en) | 2020-05-26 | 2020-05-26 | Intervention system based on brain health risk assessment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111653360A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112487287A (en) * | 2020-11-26 | 2021-03-12 | 深圳韦格纳医学检验实验室 | Method for recommending severe illness risk by using gene detection result and questionnaire |
| CN114822833A (en) * | 2021-01-29 | 2022-07-29 | 株式会社理光 | Brain function evaluation system, method and computer readable medium |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107574236A (en) * | 2016-07-02 | 2018-01-12 | 江苏华生基因数据科技股份有限公司 | It is a kind of that the method for assessing Alzheimer's disease risk is sequenced based on sanger |
| CN108766570A (en) * | 2018-05-24 | 2018-11-06 | 文丹 | A kind of resident's personal health management service system |
| CN109256213A (en) * | 2018-08-21 | 2019-01-22 | 四川靠谱健康管理有限公司 | A kind of health control method of combination genetic risk and environmental risk factors |
| CN109285606A (en) * | 2018-11-28 | 2019-01-29 | 极力健生物科技（广州）有限公司 | A kind of health control method and system based on big data intelligent algorithm |
-
2020
- 2020-05-26 CN CN202010457655.7A patent/CN111653360A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107574236A (en) * | 2016-07-02 | 2018-01-12 | 江苏华生基因数据科技股份有限公司 | It is a kind of that the method for assessing Alzheimer's disease risk is sequenced based on sanger |
| CN108766570A (en) * | 2018-05-24 | 2018-11-06 | 文丹 | A kind of resident's personal health management service system |
| CN109256213A (en) * | 2018-08-21 | 2019-01-22 | 四川靠谱健康管理有限公司 | A kind of health control method of combination genetic risk and environmental risk factors |
| CN109285606A (en) * | 2018-11-28 | 2019-01-29 | 极力健生物科技（广州）有限公司 | A kind of health control method and system based on big data intelligent algorithm |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112487287A (en) * | 2020-11-26 | 2021-03-12 | 深圳韦格纳医学检验实验室 | Method for recommending severe illness risk by using gene detection result and questionnaire |
| CN112487287B (en) * | 2020-11-26 | 2024-03-22 | 深圳韦格纳医学检验实验室 | Method for recommending serious diseases by using gene detection result and questionnaire |
| CN114822833A (en) * | 2021-01-29 | 2022-07-29 | 株式会社理光 | Brain function evaluation system, method and computer readable medium |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Corella et al. | CLOCK gene variation is associated with incidence of type-2 diabetes and cardiovascular diseases in type-2 diabetic subjects: dietary modulation in the PREDIMED randomized trial | |
| Laine et al. | Polymorphisms of the interleukin-1 gene family, oral microbial pathogens, and smoking in adult periodontitis | |
| Pollard et al. | Fatigue in rheumatoid arthritis reflects pain, not disease activity | |
| Grönhagen et al. | Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population‐based cohort of 1088 patients in Sweden | |
| Palmer et al. | Using multiple genetic variants as instrumental variables for modifiable risk factors | |
| Abuabara et al. | The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study | |
| Basra et al. | The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease | |
| Nagase et al. | Lack of association between the Trp64Arg mutation in the β3-adrenergic receptor gene and obesity in Japanese men: a longitudinal analysis | |
| Ober et al. | Genome-wide association study of plasma lipoprotein (a) levels identifies multiple genes on chromosome 6q [S] | |
| Furue et al. | Decreased risk of colorectal cancer with the high natural killer cell activity NKG2D genotype in Japanese | |
| Ammar et al. | CARD14 alterations in Tunisian patients with psoriasis and further characterization in European cohorts | |
| CN111653360A (en) | Intervention system based on brain health risk assessment | |
| US20130053270A1 (en) | Methods for determining gene-nutrient interactions | |
| Li et al. | Association of polymorphisms in the kisspeptin/GPR54 pathway genes with risk of early puberty in Chinese girls | |
| Herder et al. | RANTES/CCL5 gene polymorphisms, serum concentrations, and incident type 2 diabetes: results from the MONICA/KORA Augsburg case–cohort study, 1984–2002 | |
| Costanza et al. | Relative contributions of genes, environment, and interactions to blood lipid concentrations in a general adult population | |
| Ornstein et al. | Medicare expenditures and health care utilization in a multiethnic community-based population with dementia from incidence to death | |
| Laursen et al. | Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis | |
| Colodro-Conde et al. | Cohort Profile: Nausea and vomiting during pregnancy genetics consortium (NVP Genetics Consortium) | |
| Habberstad et al. | Variation in the sweet taste receptor gene and dietary intake in a Swedish middle-aged population | |
| Purdue et al. | Sun exposure, vitamin D receptor gene polymorphisms and risk of non-Hodgkin lymphoma | |
| JP2023526185A (en) | Personalized recommended daily intake of nutrients based on an individual's genetic risk score | |
| Abellán et al. | Dietary polyunsaturated fatty acids may increase plasma LDL-cholesterol and plasma cholesterol concentrations in carriers of an ABCG1 gene single nucleotide polymorphism: study in two Spanish populations | |
| Alizadeh et al. | Association of interferon-γ and interleukin 10 genotypes and serum levels with partial clinical remission in type 1 diabetes | |
| de Luis et al. | Effect of Fatty Acid–Binding Protein 2 Ala54Thr Genotype on Weight Loss and Cardiovascular Risk Factors after a High–Polyunsaturated Fat Diet in Obese Patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200911 |